MAPT and Alzheimer disease: Subjects with a clinical suspicion of AD undergo several clinical and instrumental tests (light grey box, Fig. 1) and are typically subjected to CSF collection and dosage of specific protein biomarkers, including t-tau, p-tau, Aβ1-40 and Aβ1-42 (dark grey box, Fig. 1).